Physician profile
Carla Smith-Ricks
NPI 1902096746
$7,603.81
in general payments reported to CMS, 2019-2025
24 companies · $1,873 in 2025
The $1,873 reported for 2025 was more than what 90% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $748 · 2022: $1,797 · 2023: $1,909 · 2024: $1,276 · 2025: $1,873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,058.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,058.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,814.30 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,038.69 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Kaleo, INC. | $878.34 | 2021-2024 | Auvi-Q |
| Abbvie INC. | $642.11 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $560.25 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $424.16 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Novartis Pharmaceuticals Corporation | $414.61 | 2022-2025 | |
| Amgen INC. | $329.75 | 2021-2024 | Tezspire |
| Incyte Corporation | $311.30 | 2021-2025 | Opzelura |
| Pfizer INC. | $237.59 | 2021-2025 | |
| Ars Pharmaceuticals Operations, INC. | $205.80 | 2025 | Neffy |
| Optinose US, INC. | $180.66 | 2021-2025 | |
| Csl Behring | $80.12 | 2022-2025 | Haegarda |
| Hikma Pharmaceuticals USA | $59.06 | 2023 | Ryaltris |
| Takeda Pharmaceuticals U.S.A., INC. | $55.25 | 2021-2025 | Cuvitru |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $54.71 | 2024-2025 | Anzupgo, Adbry |
| Genentech USA, INC. | $54.27 | 2023-2025 | Xolair |
| Organon LLC | $54.14 | 2025 | Vtama |
| Phadia US INC. | $52.38 | 2021-2023 | Immunocap |
| Aimmune Therapeutics, INC. | $42.43 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.99 | 2022 | |
| Alk-Abello, INC | $32.52 | 2021-2023 | Odactra, Ragwitek, Grastek |
| Galderma Laboratories, L.P. | $23.88 | 2025 | Nemluvio |
| Sanofi-Aventis U.S. LLC | $22.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carla Smith-Ricks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.